RA Capital Management 13F holdings, Q2 2011
Holdings as of June 30, 2011 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 20 US equity positions worth $108.1m in its Q2 2011 13F filing. The largest position was SEQUENOM INC at 14.8% of the reported book, followed by ARTHROCARE CORP and COLUMBIA LABS INC. Against the Q1 2011 filing, it opened 8 new positions, added to 6 and reduced 5 among the top 20 holdings.
What did RA Capital Management own in Q2 2011? Top 20 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2011 |
|---|---|---|---|---|---|---|---|
| 1 | SEQUENOM INC | 14.8% | $16.0m | 2,112,879 | -14% | reduced | |
| 2 | ARTHROCARE CORP | 12.6% | $13.6m | 406,969 | 40% | added | |
| 3 | COLUMBIA LABS INC | 8.2% | $8.9m | 2,884,247 | 168% | added | |
| 4 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 7.9% | $8.6m | 5,269,999 | 2% | added |
| 5 | ALEXZA PHARMACEUTICALS INC | 6.6% | $7.1m | 3,920,078 | – | new | |
| 6 | ADVENTRX PHARMACEUTICALS INC | 6.6% | $7.1m | 2,365,000 | 0% | held | |
| 7 | DERMA SCIENCES INC | 6.6% | $7.1m | 772,212 | 1618% | added | |
| 8 | PHARMASSET INC | 5.2% | $5.6m | 50,000 | -66% | reduced | |
| 9 | AFFYMAX INC | 3.9% | $4.2m | 617,372 | -63% | reduced | |
| 10 | FURIEX PHARMACEUTICALS INC | 3.6% | $3.9m | 221,400 | – | new | |
| 11 | ENZB ENZO BIOCHEM INC | 3.3% | $3.6m | 844,257 | 349% | added | |
| 12 | ANACOR PHARMACEUTICALS INC | 3.2% | $3.5m | 534,972 | – | new | |
| 13 | BSTC BIOSPECIFICS TECHNOLOGIES CO | 3.1% | $3.4m | 150,000 | -36% | reduced | |
| 14 | AEGERION PHARMACEUTICALS INC | 2.9% | $3.1m | 200,000 | – | new | |
| 15 | GTX INC DEL | 2.8% | $3.0m | 625,000 | – | new | |
| 16 | VNDA VANDA PHARMACEUTICALS INC | Healthcare | 2.5% | $2.7m | 381,052 | – | new |
| 17 | TENGION INC | 2.3% | $2.5m | 2,079,103 | 96% | added | |
| 18 | DYNAVAX TECHNOLOGIES CORP | 1.4% | $1.6m | 563,500 | -74% | reduced | |
| 19 | AVEO PHARMACEUTICALS INC | 1.4% | $1.5m | 75,000 | – | new | |
| 20 | NABI BIOPHARMACEUTICALS | 0.9% | $961.0k | 178,699 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.